Sera Prognostics Reports 163% Year-Over-Year Revenue Growth in Q3 2026
Sera Prognostics (SERA) reported strong third-quarter 2026 results, highlighted by a 163% year-over-year revenue increase to $42,000. The company saw significant growth in test volume, which increased fivefold compared to Q1 2026, and a threefold increase in ordering providers. This momentum is driven by the commercialization of its PreTRM test and recent Medicaid coverage expansions in Florida and Illinois. Despite a net loss of $8.1 million ($0.16 per share), management successfully reduced operating expenses by 11% sequentially through cost-saving initiatives. The company maintains a strong liquidity position with $72.8 million in cash and marketable securities, which is expected to fund operations into 2029. While average selling prices declined due to payer mix shifts, leadership expects a reversal of this trend in 2027 as commercialization scales.
Tickers: $SERA
Topics: clinical data medicaid coverage operating expenses revenue growth